"Isoxazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.
| Descriptor ID |
D007555
|
| MeSH Number(s) |
D03.383.129.385
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Isoxazoles".
Below are MeSH descriptors whose meaning is more specific than "Isoxazoles".
This graph shows the total number of publications written about "Isoxazoles" by people in this website by year, and whether "Isoxazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 6 | 0 | 6 |
| 1997 | 8 | 2 | 10 |
| 1998 | 6 | 2 | 8 |
| 1999 | 5 | 2 | 7 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 2 | 5 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isoxazoles" by people in Profiles.
-
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
-
Platelet-type 12-lipoxygenase deletion provokes a compensatory 12/15-lipoxygenase increase that exacerbates oxidative stress in mouse islet ß cells. J Biol Chem. 2019 04 19; 294(16):6612-6620.
-
Inhibition of 12/15-Lipoxygenase Protects Against ß-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes. 2017 11; 66(11):2875-2887.
-
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep. 2017 03 15; 7(1):201.
-
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol. 2016 11; 121(2):232-238.
-
Ethanol-Induced Motor Impairment Mediated by Inhibition of a7 Nicotinic Receptors. J Neurosci. 2016 07 20; 36(29):7768-78.
-
Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis. Ocul Immunol Inflamm. 2017 Feb; 25(1):93-96.
-
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Clin Oncol. 2015 May 20; 33(15):1666-73.
-
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34.
-
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy. JAMA Ophthalmol. 2014 Jul; 132(7):899-901.